Beyond Victoza: Novo Nordisk Sheds Light On GLP-1/Insulin Product
This article was originally published in The Pink Sheet Daily
Diabetes drug maker Novo Nordisk reports strong second quarter results based on its GLP-1 product, but could be facing some problems with other drugs in the pipeline.
You may also be interested in...
An expected surge in the number of diabetic patients has prompted the world’s biggest insulin manufacturer to build up resources in emerging markets, most recently unveiling its largest overseas R&D center, while rival Sanofi eyes acquisitions.
FDA’s advisory committee meeting on Nov. 8 falls just after the already-extended user fee date for Novo Nordisk’s long-acting insulin degludec and degludec/insulin aspart.
New treatments for Type 2 diabetes are driving the optimism underlying Bristol and AstraZeneca’s proposed acquisition for Amylin and are leading to a re-alignment of allies and competitors focused on the disease. Companies are enthusiastic about the vast opportunity, yet worried about the costs and risks of full-scale commitment to it.